TRIDEK-ONE
Tridek is a developer of immunomodulatory products intended for moderating overactive responses without blockade. The company's product is a peptide which maintains cluster of truncated CD31 to the membrane for a diversity of auto-immune and inflammatory disorders, enabling medical companies to treat their patients with better drugs and give them a better life.
TRIDEK-ONE
Social Links:
Industry:
Biotechnology Health Care Life Science
Founded:
2018-01-01
Address:
Évry, Ile-de-France, France
Country:
France
Website Url:
http://www.tridekone.com
Total Employee:
1+
Status:
Active
Total Funding:
19 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API WordPress LetsEncrypt Font Awesome IPv6 Apache
Similar Organizations
Bright Peak Therapeutics
Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Investors List
Bpifrance
Bpifrance investment in Venture Round - Tridek-One
AdBio partners
AdBio partners investment in Venture Round - Tridek-One
Bioqube Ventures
Bioqube Ventures investment in Venture Round - Tridek-One
Kinled Holding
Kinled Holding investment in Venture Round - Tridek-One
Pureos Bioventures
Pureos Bioventures investment in Venture Round - Tridek-One
Advent Life Sciences
Advent Life Sciences investment in Venture Round - Tridek-One
Advent Life Sciences
Advent Life Sciences investment in Venture Round - Tridek-One
AdBio partners
AdBio partners investment in Venture Round - Tridek-One
Official Site Inspections
http://www.tridekone.com Semrush global rank: 13.95 M Semrush visits lastest month: 67
- Host name: cluster030.hosting.ovh.net
- IP address: 145.239.37.162
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Tridek-One"
Tridek-One - Crunchbase Company Profile & Funding
Tridek-One is a biopharmaceutical company aiming to develop immunomodulatory compounds targeting the CD31 pathway. View contacts for Tridek-One to access new leads and connect …See details»
TRIDEK-ONE CLOSES A 16 MILLION FINANCING ROUND TO …
Important preclinical milestones and build a first-class biotech organization for the treatment of auto-immune diseases,” said Laurence de Schoulepnikoff, CEO of Tridek-One. ...See details»
Tridek One Company Profile | Management and Employees List
Tridek One Profile and History . Founded in 2018 by Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti, researchers in INSERM Unit 1148, located at Bichat Hospital in Paris, …See details»
Tridek-One Overview | SignalHire Company Profile
Organization Website: tridekone.com : Phone Number +33 1 6 88 46 75 96: Tridek-One industries Biotech: Headquarters Location: 4, Rue Thénard, Paris, Île-de-France, 75005 FR ...See details»
TRIDEK-ONE CLOSES A €16 MILLION FINANCING ROUND TO …
Paris, France, September 15, 2022 – Tridek-One SAS, a biotech start-up and leader in the research and development of CD31 agonists to restore the immune balance, closed a € 16 …See details»
Tridek-One Therapeutics SAS – Swiss Biotech
[email protected]; Laurence de Schoulepnikoff; Location. Rue des Fontenailles 16, 1007 Lausanne, Switzerland. Get Directions ... Canton. Vaud; Facts & figures. Type of …See details»
Tridek-One - Products, Competitors, Financials, Employees, …
The funds will primarily be used to identify development candidates against auto-immune diseases, to conduct IND-enabling studies and to further build the organization. The company …See details»
Tridek-One closes a €16 million financing round to develop first-in ...
Sep 15, 2022 The funds will primarily be used to identify development candidates against auto-immune diseases, to conduct IND-enabling studies and to further build the organization. The …See details»
French biotech startup Tridek-One closes €16m to develop first-in …
Sep 16, 2022 Laurence will now be leading Tridek-One’s strategy and development, and strengthening its general organization. Laurence de Schoulepnikoff , CEO, Tridek-One: ''I am …See details»
Tridek-One Company Profile 2024: Valuation, Funding & Investors
Tridek-One General Information Description. Operator of a biotechnology company intended to develop products for the treatment of auto-immune diseases. The company offers a peptide …See details»
Tridek-One - Drug pipelines, Patents, Clinical trials - Synapse
Explore Tridek-One with its drug pipeline, therapeutic area, technology platform, .See details»
TRIDEK-ONE THERAPEUTICS Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for TRIDEK-ONE THERAPEUTICS of PARIS, ILE DE FRANCE. Get the latest business insights from Dun & …See details»
Tridek-One: Contact Details and Business Profile
Tridekone.com; 3 4122363XXXX; 4179614XXXX; 4122363XXXX; Tran Trang Group Lead, Principal Scientist at Tridek-One Montigny-le-Bretonneux, FR View. 1 gmail.com; Guillaume …See details»
Tridek-One SAS. (9/15/22). "Press Release: Tridek-One Closes a …
Laurence will now be leading Tridek-One’s strategy and development, and strengthening its general organization. “I am delighted and grateful to have the opportunity to lead Tridek-One …See details»
Tridek-One - Craft
Tridek-One has 5 employees at their 1 location. See insights on Tridek-One including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Tridek-One bags €16M to develop auto-immune diseases candidates
Sep 15, 2022 The funds will primarily be used to identify development candidates against auto-immune diseases, to conduct IND-enabling studies and to further build the organization. The …See details»
Tridek One - Company Profile - Tracxn
Oct 22, 2024 Email ID: *****@tridekone.com; Key Metrics. Total Funding. $19.5M in 2 rounds. Latest Funding Round. Series A, Sep 15, 2022, $16.1M. Investors. Advent Life Sciences & 5 …See details»
Régis Olivier - Tridek One
Régis brings more than 25 years of experience in the areas of finance, structuring and management of health technology companies. Prior to joining Tridek-One, Régis was CEO of …See details»
TRIDEK-ONE signed an exclusive license and a collaboration …
TRIDEK-ONE signed an exclusive license and a collaboration agreement to develop CD31 agonistsSee details»